SureMASTR: Amplicon-Based Oncology Solutions

Sequence the genes that matter
For Europe only
Next-Generation Sequencing. Focus on the Genes that Matter.

Agilent offers a comprehensive range of amplicon-based oncology solutions, from cancer predisposition to molecular pathology assays. All SureMASTR assays focus on the genes that are relevant and include actionable mutations. The unique amplicon amplification PCR technique of the SureMASTR assays increases the reliability of your routine testing. Using a targeted gene assay increases the efficiency of your workflow by allowing you to perform more samples per run. The simple-to-follow protocols for different NGS systems reduce the time and effort to process the samples and enables your laboratory to perform oncology testing on a large scale.

SureMASTR assays for oncology products

Agilent’s wide range of SureMASTR catalogue oncology solutions are built on years of expertise and cover both cancer predisposition assays for human genetics (germline) and molecular tumor pathology assays for oncogenetics (somatic).

- Uniform coverage and high target specificity: helping you to optimize the efficiency of your sequencer capacity, saving time and costs.
- Minimal DNA input as low as 4 ng per PCR reaction: providing accurate results even when handling difficult samples.
- Continuous support and simple workflow: guiding your lab towards reliable results every step of the way. Easy implementation of the SureMASTR assays.

Quality control for FFPE samples

Check the DNA quality of your FFPE samples prior to your NGS run with the QC Plex. The QC Plex provides you not only with information on the amount of DNA present, but also on the DNA integrity and information regarding the absence of PCR inhibitors. This in combination with the simple-to-follow protocol ensures cost and time efficiency for your lab.

Data analysis for SureMASTR assays

MASTR Reporter is the trusted analysis solution for SureMASTR assays on Illumina NGS Systems. It enables optimized, automated variant calling of SNVs and CNVs including quality control of the entire workflow.

Expert support team

Agilent offers your lab a wide range of support tools from the initial set-up and day-to-day management to the continuous improvement of your operations. Agilent trains your collaborators and does not stop until everything is running smoothly. We can also help you select the right equipment and optimize your workflow and experts are always at your disposition. Furthermore, the online tools help you calculate the number of samples to be pooled per run and assess your FFPE-derived DNA quality. Agilent also guides your lab towards reliable results. Every step of the way.

Oncology SureMASTR assays

**Cancer Predisposition**

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Genomic Target</th>
<th>Related Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRCA MASTR Dx</td>
<td>BRCA1, BRCA2</td>
<td>Breast &amp; Ovarian</td>
</tr>
<tr>
<td>BRCA MASTR Plus Dx</td>
<td>BRCA1, BRCA2</td>
<td>Breast &amp; Ovarian</td>
</tr>
<tr>
<td>BRCA MASTR Plus Dx</td>
<td>BRCA1, BRCA2</td>
<td>Breast &amp; Ovarian</td>
</tr>
</tbody>
</table>

**For Research Use Only. Not for use in diagnostic procedures.**

- BRCA MASTR Plus Dx
- SureMASTR Hereditary Cancer

**Molecular Tumor Pathology**

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Genomic Target</th>
<th>Related Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Somatic 1 MASTR Plus Dx</td>
<td>NRAS, KRAS and BRAF</td>
<td>Colorectal, thyroid and melanoma</td>
</tr>
</tbody>
</table>

**For Research Use Only. Not for use in diagnostic procedures.**

- Somatic 1 MASTR Plus Dx
- SureMASTR Tumor Hotspot

**DNA Quality Control**

| QC Plex | DNA-QC Multiplex for FFPE-Derived DNA | Breast & Ovarian |

MASTR Reporter is available for following SureMASTR assays

**For In Vitro Diagnostic Use.**

- BRCA MASTR Dx
- BRCA MASTR Plus Dx

**For Research Use Only. Not for use in diagnostic procedures.**

- SureMASTR Tumor Hotspot
- SureMASTR Hereditary Cancer

Oncology

Germline & Somatic assays for analysis of various cancer-related genes.
Learn more:
www.agilent.com
Europe
genomics_tech_europe@agilent.com